Corporate News


Tuesday 11 October 2016

New European Society of Medical Oncology (ESMO) Biliary Cancer Guidelines Indicate Selective Internal Radiation Therapy (SIRT) with Y-90 Microspheres as an Option for Post-Chemotherapy Treatment of Intrahepatic Cholangiocarcinoma (iCCA)
Sirtex Medical Limited (ASX:SRX) announced today that the European Society of Medical Oncology (ESMO) has indicated the use of SIRT using yttrium-90 (Y-90) microspheres as an option for the treatment of intrahepatic cholangiocarcinoma (iCCA), a form of primary liver cancer that starts in the bile duct, the branching network of thin tubes that deliver fat-digesting bile from the liver to the small intestine.
Read more


Download PDF Download PDF

Languages:

Thursday 29 January 2015

FOXFIRE and FOXFIRE Global Studies Complete Patient Enrolment
Combined data from more than 1,000 patients being collected to assess overall survival (OS) benefit of adding first-line SIR-Spheres® Y-90 resin microspheres treatment to a current chemotherapy regimen for inoperable metastatic colorectal cancer (mCRC)
Read more


Download PDF Download PDF

Languages:

Monday 08 September 2014

Sirtex Medical Inc. Expands Business into Brazil, Experiences Record Growth
First SIR-Spheres® microspheres treatment at Hospital Sirio-Libanes in Sao Paulo, Brazil
Read more

Monday 24 March 2014

Sirtex and Guerbet to Collaborate on Clinical Studies in Primary and Secondary Liver Cancer
The two companies will enter into a major clinical studies collaboration in primary and secondary (metastatic) liver cancer.
Read more

Saturday 13 April 2013

Sirtex Completes Patient Recruitment for SIRFLOX Study Evaluating SIR-Spheres® Microspheres as First-Line Treatment for Colorectal Liver Metastases
World’s Largest Interventional Oncology Study with More Than 500 Patients Enrolled
Read more

Tuesday 11 December 2012

Sirtex Medical Limited Launches New Global Website for SIR-Spheres® microspheres – a form of Selective Internal Radiation Therapy (SIRT) for Liver Tumours
www.sirtex.com informs doctors, patients and investors about the world’s most widely used and widely studied form of SIRT for all cancers in the liver
Read more

Wednesday 15 August 2012

Sirtex Medical Inc. Expands U.S. Operations to Accommodate Increased Demand for SIR-Spheres® Microspheres
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, announced today expansion of U.S. operations with the placement of additional sales, marketing, and functional support staff in Massachusetts and across the country.
Read more

Thursday 07 July 2011

Six Year Study Confirms Sirtex´s Liver Cancer Therapy Safe and Effective

Thursday 24 June 2010

Sirtex Invests in New Major Asia Pacific Study to Expand Clinical Use

Tuesday 08 June 2010

SIRTEX Reports Positive Results From Asian Clinical Trial
Combination of SIR-Spheres® Microspheres and Chemotherapy Shows Improved Survival for Inoperable Hepatocellular Carcinoma (HCC) Liver Cancer Patients. Median overall survival of 11.75 months in a HCC patient population with limited treatment options
Read more

Monday 01 March 2010

New UK Trial With Oxford University To Test New Bowel Cancer Therapy
Oncology treatment company Sirtex Medical Limited (ASX: SRX) today announced the start of a new trial to see if chemotherapy used with SIR-Spheres® microspheres targeted radiation therapy is more effective than just chemotherapy in patients with bowel cancer that has spread to the liver.
Read more

Thursday 11 February 2010

Sirtex Joins Bayer Healthcare in Major European Liver Cancer Trial

Tuesday 01 July 2008

Fourth Annual Symposium on Liver-Directed Microsphere Therapy Raises Awareness of the Latest Advances for Treating Metastatic Liver Tumors
Clinical Symposium Featured New Data and Research on the use of Sirtex’s SIR-Spheres® Microspheres
Read more

Friday 13 June 2008

SIR-Spheres® Microspheres Featured at the 2008 Society of Nuclear Medicine Annual Meeting
Sirtex, a leading developer of targeted and innovative cancer therapies, will exhibit its SIR-Spheres microspheres technology at the 2008 Society of Nuclear Medicine (SNM) Annual Meeting. The meeting, to be held June 14-18 at the Convention Center in New Orleans, La., is considered the premier educational and scientific event in the nuclear medicine community. Sirtex manufactures SIR-Spheres microspheres, the only FDA-approved microsphere therapy for advanced colorectal cancer that has metastasized to the liver.
Read more

Thursday 24 April 2008

Sirtex Supports the Fourth Annual Clinical Symposium on Liver-Directed Microsphere Therapy Dedicated to Advancing Treatments for Patients with Inoperable Metastatic Liver Cancer
Meeting to Highlight Latest Clinical Advances with the Use of Yttrium-90 Microsphere Therapy to Control one of the Deadliest Forms of Cancer
Read more

Monday 31 March 2008

Sirtex Medical receives US FDA Approval to Proceed with FAST Clinical Trial
Update on Clinical Trial Evaluating SIR-Spheres Microspheres with Bevacizumab and Chemotherapy as a First-Line Treatment for Unresectable Metastatic Colorectal Cancer
Read more

Wednesday 03 October 2007

Sirtex Medical Signs Agreements with Peter MacCallum Cancer Centre to Develop and Market Innovative Cancer Treatment Technology

Wednesday 18 April 2007

Sirtex Medical Announces Expansion of its R&D Programs to Develop new Oncology Therapies and Product Enhancements

Tuesday 27 March 2007

Sirtex to Participate in the 2007 American Society of Clinical Oncology Annual Conference
New Data Regarding Repeat Treatments of SIR-Spheres® Microspheres in Patients with Advanced Liver Tumors to be Included at Annual Meeting
Read more

Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×

This content is intended for journalists only

By clicking "Yes" you are confirming that you are a journalist. If you are not a journalist, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage